The Clash Over Science, Covid Policies and Vaccines at the FDA

Why it Matters

The Senate Permanent Subcommittee on Investigations is diving into one of the most combustible intersections in American public life: federal health agencies, COVID-19 vaccine science, and allegations that government officials actively suppressed their own researchers' published findings. This hearing preview arrives at a moment when the FDA has already confirmed it directed scientists to withdraw peer-reviewed studies from academic journals, a fact that has ignited a fierce debate over whether that constitutes scientific stewardship or institutional censorship. The stakes extend well beyond pandemic retrospectives: how Congress interprets what happened inside federal health agencies could reshape oversight of the FDA, NIH, and the broader machinery of government-funded science for years to come.

The Broader Context

On May 5, 2026, the New York Times, Reuters, The Guardian, and ABC News simultaneously reported that FDA officials had directed the agency's own scientists to withdraw two COVID-19 vaccine safety studies that had already been accepted for publication in the peer-reviewed journals Drug Safety and Vaccine. The BMJ followed with additional reporting on May 8. A separate account from the Center for Science in the Public Interest (CSPI) on May 15 added that FDA staff were also prevented from submitting evidence on shingles vaccine safety and effectiveness to journals.

HHS spokesperson Andrew Nixon confirmed the withdrawals, stating that "the studies were withdrawn because the authors drew broad conclusions that were not supported by the underlying data," framing the agency's intervention as a quality-control measure. Critics, including Guardian op-ed contributor Robert B. Shpiner on May 12, called it outright suppression of pro-safety findings. They argued that the research, if published, would have supported vaccine safety rather than undermined it.

That distinction matters enormously for how the upcoming hearing date lands politically. The subcommittee's framing is capacious enough to encompass both the withdrawal of pro-safety studies and the broader, longer-running allegations that COVID-era science was manipulated in either direction. Which thread the committee pulls hardest will define whether this legislative hearing functions as a genuine accountability exercise or a continuation of partisan COVID revisionism.

A Sustained Investigation

The PSI under Chairman Ron Johnson (R-WI) has been running a sustained inquiry into COVID-19 vaccine policy for months. On May 8, Johnson's office released what it called a "blockbuster" report, accompanied by approximately 600 pages of records, alleging that beginning in early 2021, FDA officials became aware of a more sophisticated data-mining method capable of detecting vaccine safety signals, and chose instead to continue using an older, less sensitive methodology. The report characterized this as a deliberate decision by Biden-era health officials to avoid detecting adverse events.

Roughly two weeks later, on approximately May 21, the same subcommittee held a hearing titled "Unmasked: How Biden Health Officials Purposely Turned a Blind Eye Toward COVID-19 Vaccine Safety Signals." Video released from that session on May 26 captured Johnson declaring, "We've got a real big problem in this country about vaccine-injury deniers. Again, these vaccine injuries are real, but it's being denied."

The June 3 session is the next installment in that sequence: this hearing preview focused specifically on the publication interference dimension that the May 5 news cycle put squarely in front of the public.

The Committee and Its Fault Lines

The PSI is chaired by Johnson, with Sen. Richard Blumenthal (D-CT) serving as ranking member. The full committee membership includes Sens. Rand Paul, Rick Scott, Josh Hawley, James Lankford, and Bernie Moreno on the Republican side, and Sens. Maggie Hassan, John Fetterman, Andy Kim, and Gary Peters on the Democratic side.

Johnson has been the Senate's most persistent skeptic of COVID-19 vaccine policy since 2021, a posture that gives this policy hearing preview a clear ideological center of gravity. Democratic members are likely to push back on the framing that withdrawn studies constitute "attacks" and to question whether the hearing is designed to generate accountability or to amplify vaccine hesitancy ahead of future public health campaigns.

The Bottom Line

The immediate public consequence is reputational and institutional. If the subcommittee builds a credible record that federal scientists were muzzled for reasons beyond legitimate methodological concerns, it would represent a serious indictment of how health agencies managed scientific communication during and after the pandemic. That finding could accelerate ongoing efforts within the Trump administration to restructure or reduce the authority of agencies like the FDA and CDC.

The inverse risk is equally real: a hearing that treats contested allegations as settled fact could further erode public trust in vaccines at a moment when measles outbreaks and declining childhood vaccination rates are already straining the public health system. The hearing schedule lands at a moment when the institutional credibility of American science is genuinely on the line.